• Molecular NameSulfanilamide
  • SynonymP-Aminobenzenesulfamide; P-Aminobenzenesulfonamide; P-Aminobenzenesulfonylamide; P-Aminobenzensulfonamide; P-Aminophenylsulfonamide; P-Anilinesulfonamide; P-Sulfamidoaniline; P-Sulfamoylaniline; PABS; Sulfanilimidic Acid; Sulfonylamide; Sulphanilamide; Sulphonamide
  • Weight172.208
  • Drugbank_IDDB00259
  • ACS_NO63-74-1
  • Show 3D model
  • LogP (experiment)-0.6
  • LogP (predicted, AB/LogP v2.0)-0.67
  • pka10.6
  • LogD (pH=7, predicted)-0.67
  • Solubility (experiment)7.5 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-1.19
  • LogSw (predicted, AB/LogsW2.0)4.84
  • Sw (mg/ml) (predicted, ACD/Labs)11.17
  • No.of HBond Donors4
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds1
  • TPSA94.56
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA sulfonamide antibacterial. Chemically, it is a molecule containing the sulfonamide functional group attached to an aniline.
  • Absorption_valueN/A
  • Absorption (description)Sulfonamides are absorbed through the vaginal mucosa. There are no pharmacokinetic data available describing how much of an intravaginal dose reaches the systemic circulation.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects include itching, burning, skin rash, redness, swelling, or other sign of irritation not present before use of this medicine and long-term use of sulfonamides may cause cancer of the thyroid gland.
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=3700 mg/kg